4.8 Article

Endogenous Positive Allosteric Modulation of GABAA Receptors by Diazepam binding inhibitor

Journal

NEURON
Volume 78, Issue 6, Pages 1063-1074

Publisher

CELL PRESS
DOI: 10.1016/j.neuron.2013.04.026

Keywords

-

Categories

Funding

  1. NIH [NS034774, NS005477, T32 NS007280]
  2. Epilepsy Foundation Research Fellowship
  3. Katharine McCormick Advanced Postdoctoral Fellowship from Stanford School of Medicine

Ask authors/readers for more resources

Benzodiazepines (BZs) allosterically modulate gamma-aminobutyric acid type-A receptors (GABA(A)Rs) to increase inhibitory synaptic strength. Diazepam binding inhibitor (DBI) protein is a BZ site ligand expressed endogenously in the brain, but functional evidence for BZ-mimicking positive modulatory actions has been elusive. We demonstrate an endogenous potentiation of GABAergic synaptic transmission and responses to GABA uncaging in the thalamic reticular nucleus (nRT) that is absent in both nm1054 mice, in which the Dbi gene is deleted, and mice in which BZ binding to alpha 3 subunit-containing GABA(A)Rs is disrupted. Viral transduction of DBI into nRT is sufficient to rescue the endogenous potentiation of GABAergic transmission in nm1054 mice. Both mutations enhance thalamocortical spike-and-wave discharges characteristic of absence epilepsy. Together, these results indicate that DBI mediates endogenous nucleus-specific BZ-mimicking (endozepine) roles to modulate nRT function and suppress thalamocortical oscillations. Enhanced DBI signaling might serve as a therapy for epilepsy and other neurological disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available